Drugs was 111’s largest product and service line in fiscal 2025, bringing in $11.65B of $12.56B (93%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Drugs | $12.57B | $13.88B | $13.40B | $11.65B | ||||||
| Nutritional Supplements | $554.79M | $631.12M | $550.46M | $434.69M | ||||||
| Medical Supplies & Devices | $164.92M | $157.50M | $144.28M | $152.35M | ||||||
| Other Products | $111.10M | $170.23M | $201.83M | $233.69M | ||||||
| Contact Lenses | — | — | — | — | ||||||
| Mp Service | $68.48M | $70.27M | $65.54M | $56.75M | ||||||
| Other Services | $44.79M | $35.95M | $40.97M | $28.63M | ||||||
| Total | $13.52B | $14.95B | $14.40B | $12.56B |
111 brought in $12.56B from its six product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 12.8% from $14.40B in fiscal 2024. Drugs was the largest at $11.65B (92.8%), ahead of Nutritional Supplements at $434.69M (3.5%) and Other Products at $233.69M (1.9%). The other three lines brought in $237.73M combined.
Compared with fiscal 2024, Drugs fell 13.0% to $11.65B and Nutritional Supplements fell 21.0% to $434.69M. From fiscal 2022 to 2025, combined revenue from these lines fell from $13.52B to $12.56B, a compound annual decline of 2.4%. Drugs' share held steady at about 92.8%.
B2B Segment was 111’s largest segment in fiscal 2025, bringing in $12.32B of $12.56B (98%).
| Segment | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| B2B Segment | $13.08B | $14.57B | $14.12B | $12.32B | ||||||
| B2C Segment | $441.53M | $377.36M | $278.10M | $234.82M | ||||||
| Total | $13.52B | $14.95B | $14.40B | $12.56B |
111 brought in $12.56B from its two segments in fiscal 2025, the year ended December 31, 2025. That was down 12.8% from $14.40B in fiscal 2024. B2B Segment was the largest at $12.32B (98.1%), ahead of B2C Segment at $234.82M (1.9%).
From fiscal 2022 to 2025, combined revenue from these segments fell from $13.52B to $12.56B, a compound annual decline of 2.4%. B2B Segment's share of the total rose from 96.7% to 98.1%.
111 (YI) reports its revenue by product and service and by segment. In fiscal 2025, Drugs was its largest product and service line, bringing in $11.65B (92.8% of the total), followed by Nutritional Supplements at $434.69M (3.5%).
Drugs was 111's largest product and service line in fiscal 2025, bringing in $11.65B, or 92.8% of the $12.56B total across its six product and service lines.
B2B Segment was 111's largest segment in fiscal 2025, bringing in $12.32B, or 98.1% of the $12.56B total across its two segments.
Every figure comes from 111's annual financial filings, as reported. Each line keeps the name 111 gives it, and years follow its fiscal calendar.
111's revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.